Processa Pharmaceuticals, Inc. (PCSA)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.73
- As of
Kresmion compiles this page from PCSA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Processa Pharmaceuticals, Inc. (PCSA): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-13.
See the full PCSA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for PCSA on one page. Preview it with sample data, then open it live with a free account.
Preview the PCSA dossierActive events for PCSA
- medium13F: new position
CITADEL ADVISORS LLC new position in PCSA
- mediumEarnings above estimates
Q1-2025: Beat consensus by 61.8% - EPS $-7.5 vs $-19.635 estimate
- mediumEarnings below estimates
Q2-2025: Missed consensus by 6.6% - EPS $-6.25 vs $-5.865 estimate
- mediumEarnings above estimates
Q3-2025: Beat consensus by 14.2% - EPS $-1.75 vs $-2.04 estimate
- mediumEarnings below estimates
Q4-2025: Missed consensus by 68.0% - EPS $-2.57 vs $-1.53 estimate
FREE, NO ACCOUNT
Every event on PCSA, as it fires
You are seeing 5 of 9 events recorded on PCSA since 2026-06-02.
The five above landed across 2 days. The other 4 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.
Recent SEC filings, PCSA
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
Going concern statement
PCSA's 10-Q filed Nov 13, 2026 states:
Accordingly, we concluded that substantial doubt about our ability to continue as a going concern continues to exist within one year after the date these financial statements are available to be issued.
Read the 10-Q on SEC EDGAR Every company with a going concern statement
More data on PCSA
PCSA against its peers
PCSA's return on equity of -243.2% ranks in the 26th percentile of 20 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | PCSA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 418189 | n/a | 18 |
| Gross margin | n/a | 20.4% | n/a | 7 |
| Operating margin | n/a | -1286.6% | n/a | 14 |
| Net margin | n/a | -931.2% | n/a | 15 |
| Return on equity | -243.2% | -163.5% | 26 | 20 |
| 1 year | -75.3% | -75.4% | 50 | 20 |
Peers (22): JAGX, CDIO, BGMS, OSRH, CNSP, LGVN, SNGX, ACXP, PULM, NIKI, CANF, TCRT, CNSY, RVPH, EVGN, CSCIF, CELZ, CRIS, SNTI, IMNN, XCUR, KPRX. Left out: ADAPY (no annual filing), ADXN (period gap), ENVB (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (PCSA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Cite this data
Kresmion counts the managers it follows that reported a non-option position in PCSA on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on PCSA in the last 180 days.
Upstream: SEC EDGAR filings for PCSA
Kresmion, "Processa Pharmaceuticals, Inc. (PCSA) institutional holdings and SEC filings", data as of 2026-11-13, https://kresmion.com/research/PCSA. Upstream data: SEC EDGAR filings for PCSA.
Link to this data (HTML):
<a href="https://kresmion.com/research/PCSA">Processa Pharmaceuticals, Inc. (PCSA) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow PCSA on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to PCSA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.